REN skincare is closing down – stock up on my tested favourites before it's too late
More than two decades before the 'clean girl aesthetic' started trending on TikTok, REN was founded in East London with a pared-back, clean approach to skincare. A pioneer in the sustainable beauty space, the brand brought natural ingredients and sensitive skin-friendly formulas to the forefront.
Getting its brand name from the Swedish word for 'clean', Ren was created in 2000 when its founder's pregnant wife began experiencing sensitivity from her everyday beauty products. From its bestselling evercalm balm to the barrier support elixir, its roster of products favour bioactives that are kind to both the planet and your skin. It was among the first to eliminate parabens, synthetic fragrances, sulfates and petrochemicals from its formulas, inspiring all the green brands that followed suit.
REN's efficacious formulas are not only great for sensitive skin and eczema, but also young skin. I was first introduced to REN as a teenager just getting into skincare, when my parents wrapped up one of the brand's gift sets for Christmas. Its formulas are still a staple of my beauty routine, from the glow-getting tonic to the brightening eye cream. The beauty industry is full of buzzwords and green washing, but REN is one of the few sustainable brands you can trust, with its formulation standards enduring for a quarter of a century.
So, when REN announced its imminent closure last month, I was one of its many fans preparing to mourn its loss in the space. Unilever – which bought the brand in 2015 – said it took the 'difficult decision' after a consultation period, blaming 'a combination of internal factors, compounded by market challenges in recent years', Unilever said REN is 'unable to sustain success in the long term'.
'We are proud of the REN team for all they have accomplished during 25 years of business, putting 'clean' skin care on the agenda and creating positive change for both people and planet and thank them as they continue to support us through this closure,' Unilever said in the statement.
No date has been set yet for its official closure, but the brand said it will cease trading in the last quarter of 2025. As it winds down, I'm supporting the brand one final time by stocking up on cult classics and new favourites (see its sensitive skin daily SPF), and suggest you do too. Here are the best products to buy from REN while you still can.
This has been a staple in my skincare routine for as long as I can remember. The non-invasive facial exfoliator is formulated with smoothing AHA's (lactic avid) and pore refining BHA's (salicin) to brighten and even out your skin tone. It leaves a dewy, glowy finish, gliding effortlessly on with a cotton pad. I've never found a product that both exfoliates and tackles hyperpigmentation while also boosting radiance. I use it every morning to give my skin the best start to the day. It's a great choice for those who usually find exfoliators or BHA toners too harsh on their skin - just make sure to build up to daily use.
Delivering radiant skin by morning, Ren's recovery balm has a thick, gel-like consistency, with the product transforming into a lightweight consistency after warming it up in your hands. It's ultra-nourishing (thank you lipids like olive, almond, linseed and jojoba), locking in moisture and strengthening the skin's barrier. My skin feels soft and super hydrated come morning, with redness soothed and the appearance of pores minimised.
REN's brightening eye cream is a perfectly weighted formula that instantly nourishes the under-eye area thanks to hyaluronic acid and a skin-balancing duo of elderberry flower and glycogen. Though absorbing quickly, it leaves a subtle sheen that immediately brightens up the area, making it perfect for daily morning use. It also works as a stellar primer, so you can apply concealer straight away. I also just love the fuss-free pump applicator, which is far less messy than the tubs that most eye creams come in.
This is a new launch from the brand, but already a firm favourite in my SPF rotation. It's non-greasy and absorbs into skin fast (my two non-negotiables when it comes to sunscreen), with a satin finish and no risk of a white cast residue. Suitable for sensitive and eczema-prone skin, the formula isn't fragranced and is non-comedogenic. Not only does it protect against UV rays, but it's formulated with an anti-pollution complex to tackle environmental aggressors and has niacinamide to protect against blue light damage from electronic devices.
REN's gentle cleanser is suitable for sensitive, oily or combination skin. I double cleanse with it in the morning and find that it doesn't dry out skin like other gel-based cleansers, nor leave that feeling of tightness. The formula works to strip the skin of impurities and dirt without losing any moisture, thanks to a strengthening duo of beta-glucan and prebiotic extracts. The cleanser leaves your face feeling soft, supple and ready for the day.
REN's barrier support elixir is a product deserving of its cult status. If you've got oily skin already, or don't like the greasy sheen facial oils can leave, then REN's formula is a must-try. It's super lightweight and packed with seven nourishing oils - including camellia and rosehip - to strengthen and soothe skin. It absorbs quickly, so don't fret about using it in the morning before SPF, though I prefer to apply it as the final step of my routine in the evening. It works to tackle redness, hydrate dry patches and restore radiance to skin.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
17 minutes ago
- The Sun
Common prescription drug prevents heart attack and stroke WITHOUT deadly risk, scientists discover
A COMMON prescription drug has been linked to lower rates of heart attack and stroke - with no increased risk of major bleeding, say scientists. Low-dose aspirin is recommended by the NHS to prevent heart attacks and strokes in people who are at high risk of them. 1 Because aspirin helps to stop your blood from clotting, it can sometimes make you bleed more easily. For example, you may get nosebleeds and bruise more easily, and if you cut yourself, the bleeding may take longer than normal to stop. Now, a study published by The BMJ supports the use of P2Y12 therapy instead of aspirin for long term prevention. Giving the anti-clotting drug to patients with coronary artery disease was associated with lower rates of cardiovascular death, heart attack and stroke compared with traditional aspirin, with no increased risk of major bleeding. P2Y12 inhibitors are usually given to patients alongside aspirin after percutaneous coronary intervention (PCI) - a procedure to widen or unblock a coronary artery to help prevent cardiovascular events. After several months, patients are usually switched from dual therapy (both drugs) to lifelong aspirin, but some trials have suggested a P2Y12 inhibitor may be more effective for long term prevention than aspirin. So in the new study, researchers analysed individual patient data from five randomised clinical trials involving 16,117 patients who were assigned to either a P2Y12 inhibitor or aspirin after completing dual therapy. When they were followed up four years later, P2Y12 inhibitor therapy was associated with a 23 per cent lower risk of an outcome that combined cardiovascular death, heart attack, or stroke, compared with aspirin - with no significance different in major bleeding. When considering outcomes individually, P2Y12 inhibitor therapy reduced heart attacks and stroke compared with aspirin. The researchers said: "Overall, this study supports preferential P2Y12 inhibitor monotherapy prescription over aspirin due to reductions in major adverse cardiac and cerebrovascular events without increasing major bleeding in the medium term." Women vs. Men Heart Attack Symptoms But, they note "medium term efficacy does not necessarily extend lifelong, which is the duration we advise patients to continue these medications". To prevent heart attacks and strokes in patients with coronary artery disease, it's crucial to make lifestyle changes like quitting smoking, exercising regularly, maintaining a healthy weight, and following a balanced diet. Smoking significantly increases the risk of heart disease and stroke, so quitting is recommended. People should aim for at least 150 minutes of moderate-intensity aerobic exercise per week and choose a diet low in saturated and trans fats, high in fibre, fruits, vegetables, and whole grains, and low in salt. If you drink alcohol, you should do so in moderation. And practice relaxation techniques, like deep breathing or yoga, and find healthy ways to copy with stress. Seeing your doctor regularly for screenings and to monitor your heart health. And making sure you get enough sleep (seven to nine hours per night) is important. Various symptoms and warning signs can indicate heart disease, and being aware of them can help in early detection and treatment...
FF News
28 minutes ago
- FF News
Eight Bold Startups Define Next Generation of Fintech at Money20/20 Europe
Money20/20, the world's leading fintech show and the place where money does business, held its anticipated Startup Media Session on June 4th at Money20/20 Europe in Amsterdam. Eight startups took the spotlight on the Briefing Stage, each with a transformative solution poised to reshape industries—from emerging market payments and decentralized identity to climate tech investing and AI-powered risk management. 'These eight startups showcase the transformative power of European fintech,' said Suzy Pallett, Executive Vice President at Money20/20 Europe. 'From rethinking payments in emerging markets to advancing AI-driven risk tools, each tackles key financial challenges. We're especially excited to announce Sinpex as the winner of Money20/20's Startup Pitch competition in our media session. 'Winning the Money 20/20 Startup Pitch competition is the result of the incredible work we've done over the last few years to revolutionize KYB. From onboarding to ongoing monitoring, we're setting new standards in compliance automation, with a proven track record among leading financial institutions. This award underscores the real impact we're making in helping the industry move faster, stay compliant, and scale with confidence' says Camillo Werdich, CEO of Sinpex. 'The Money20/20 Europe Startup Media Session demonstrates the conference's deep commitment to the startup ecosystem,' said Adrian Brown, COO & Co-Founder of AbbeyCross. 'We're doing something new and different at AbbeyCross, so being able to give context and background to the assembled media is very valuable to us.' Heather Dahl, CEO of Indicio a software development firm specializing in decentralized identity said: 'This recognition from Money20/20 couldn't be better timed. We're seeing the financial sector gain traction using the power of decentralized identity technology to transform everything from account access, biometrics, payments, and even agentic AI.' Carbon Equity, a platform democratizing access to climate tech investments, is unlocking private equity and venture capital fund investing for climate innovation. 'Few things build trust and reach as powerfully as media coverage,' said Jacqueline van den Ende, Co-Founder and CEO of Carbon Equity. 'Money20/20 offers us a unique opportunity to showcase our wealth platform and vision for transformative finance to a yet bigger audience.' Also joining the session was ChainComply, a fast-growing startup revolutionizing compliance for the crypto-traditional finance ecosystem. 'It's an incredible platform for to showcase how we empower compliance teams at banks and crypto exchanges,' said Pavllina Pavlova, CEO of ChainComply. 'We're deeply grateful to Money20/20 for shining a spotlight on vision-driven startups like ours.' Esca, a technology company helping businesses in Africa mitigate currency volatility, showcased its innovative approach. 'On behalf of the entire team at Esca, I want to extend a heartfelt thank you to the incredible organizers of Money20/20 for giving us the opportunity to share our vision on this iconic stage in Amsterdam,' said Shalom Osiadi, Founder and CEO of Esca. Nekod demonstrated its AI-driven governance platform for business-built software. 'Being selected by Money20/20 for the Startup Media Session is a valuable opportunity to share NEKOD's vision with those shaping the future of finance,' said Antigoni Kourou, Founder and CEO of NEKOD. Oscilar, specializing in AI-powered risk decisioning solutions, rounded out the impressive lineup. 'Risk management is no longer about static rules and batch reviews—it's about real-time intelligence and AI-powered autonomy,' said Neha Narkhede, CEO & Founder of Oscilar. From emerging markets to AI, compliance to climate tech, the Money20/20 Europe Startup Media Session continues to be the premier showcase for innovators shaping what's next. These eight companies are united by a bold mission: to solve complex problems, break down silos, and accelerate the future of money.
Sky News
33 minutes ago
- Sky News
The big problem facing UK as deadline to finalise US trade deal looms
When push comes to shove, the question of whether British industry faces crippling tariffs on exports to the US or enjoys a unique opportunity to grow may come back to three seemingly random words: "melted and poured". To see why, let's begin by recapping where we are at present in the soap opera of US trade policy. Donald Trump has just doubled the extra tariffs charged on imports of steel and aluminium into the US from 25% to 50%. In essence, this would turn a painfully high tariff into something closer to an insurmountable economic wall (remember during the Cold War, the Iron Curtain equated to an effective tariff rate of just under 50%). Anyway, the good news for UK steel producers is that they have been spared the 50% rate and will, for the time being, only have to pay the 25% rate. But there is a sting in the tail: that stay of execution will only last until 9 July - on the basis of President Trump's most recent pronouncements. 1:00 For anyone following these events from the corner of their eyes, this might all sound a little odd. After all, didn't Sir Keir Starmer announce only a few weeks ago that British steel and aluminium makers would be able to enjoy not 25% but 0% tariffs with America, thanks to his bold new trade agreement with the US? Well, yes. But the prime minister wasn't being entirely clear about what that meant in practice. Because the reality is that every trade agreement works more or less as follows: politicians negotiate a "heads of terms" agreement - a vague set of principles and red lines. There then follows a period of horse-trading and negotiation to nail down the actual details and turn it into a black and white piece of law. In this case, when the PM and president made their big announcement 28 days ago, they had only agreed on the "heads of terms". The small print was yet to be completed. Right now, we are still in the horse-trading phase. Negotiators from the UK and the US are meeting routinely to try and nail down the small print. And that process is taking longer than many had expected. To see why, it's worth drilling a little bit into the details. The trade deal committed to allowing some cars to pass into the US at a 10% rate and to protecting some pharmaceutical trade, as well as allowing some steel and aluminium into the US at a zero tariff rate. When it comes to cars, there are some nuances about which kind of cars the deal covers. Something similar goes for pharmaceuticals. Things get even knottier when you drill into the detail on steel. 2:13 You see, one of the things the White House is nervous about is the prospect that Britain might become a kind of assembly point for steel from other countries around the world - that you could just ship some steel to Britain, get it pressed or rolled or worked over and then sent across to the US with those 0% tariffs. So the US negotiators are insisting that only steel that is "melted and poured" in the UK (in other words, smelted in a furnace) is covered by the trade deal. That's fine for some producers but not for others. One of Britain's biggest steel exporters is Tata Steel, which makes a lot of steel that gets turned into tin cans you find on American supermarket shelves (not to mention piping used by the oil trade). Up until recently, that steel was indeed "melted and poured" from the blast furnaces at Port Talbot. But Tata shut down those blast furnaces last year, intending to replace them with cleaner electric arc furnaces. And in the intervening period, it's importing raw steel instead from the Netherlands and India and then running it through its mills. Or consider the situation at British Steel. There in Scunthorpe they are melting and pouring the steel from iron made in their blast furnaces - but now ponder this. While the company has been semi-nationalised by the government, it is still technically a Chinese business, owned by Jingye. In other words, its steel might technically count as benefiting China - which is something the White House is even more sensitive about. 👉 Tap here to follow Politics at Jack and Anne's wherever you get your podcasts 👈 You see how this is all suddenly becoming a bit more complicated than it might at first have looked? This helps to explain why the negotiations are taking longer than expected. But this brings us to the big problem. The White House has indicated that Britain will only be spared that 50% tariff rate provided the trade deal is finalised by 9 July. That gives the negotiators another month and a bit. That might sound like a lot, but now consider that that would be one of the fastest announcement-to-completion rates ever achieved in any trade negotiations in modern history. There's no guarantee Britain will actually get this deal done in time for that deadline - though insiders tell me they think they could be able to finalise it in a piecemeal fashion: the cars one week, steel another, pharmaceuticals another. Either way, the heat is on. Just when you thought Britain was in the safe zone, it stands on the edge of jeopardy all over again.
